Business
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-sta
About this update from In8bio, Inc.
[{"type":"image","alt":"IN8bio, Inc","displaySize":"","headline":null,"caption":"IN8bio, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM3P9KMIYObIbb2x2kkziw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. ","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.","length":198,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":412,"olType":false},{"type":"text","content":"NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new data on its proprietary γδ T manufacturing program. The oral presentation shared exciting updates about its unique manufacturing processes, including deep analytics, genomics and repertoire analysis, presented at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The data, which earned IN8bio the prestigious Host Region (U.S. East) Abstract Award, as presented by Bruce Levine, PhD, ISCT Past President and a member of IN8bio’s Scientific Advisory Board. The award is a competitive recognition for scientific excellence and demonstrates how IN8bio’s technology and know-how creates consistent, powerful cellular therapies.","length":882,"tagName":"p"},{"type":"text","content":"The oral presentation highlights how IN8bio’s DeltEx™ Allo manufacturing process consistently induces donor derived T cells to express γδ T cell receptors (TCRs) and genes, associated with increased cancer cytotoxicity. Gene expression profiling confirmed a highly potent product...